SCHEMBL14045873

SCHEMBL14045873

CN(Cc1ccc(F)cc1)S(=O)(=O)c1ccc(CN2CCNC(=O)C2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 2/20 0.55
MAOA P21397 2/20 0.48
MAOB P27338 1/20 0.48
CASP3 P42574 1/20 0.48
NR1H2 P55055 1/20 0.48
MCHR1 Q99705 2/20 0.45
ALDH1A1 P00352 1/20 0.44
POLB P06746 1/20 0.44
MLNR O43193 1/20 0.44
PSEN1 P49768 1/20 0.44
PSEN2 P49810 1/20 0.44
APH1B Q8WW43 1/20 0.44
NCSTN Q92542 1/20 0.44
APH1A Q96BI3 1/20 0.44
PSENEN Q9NZ42 1/20 0.44
GRM2 Q14416 1/20 0.43
KCNA5 P22460 1/20 0.41
HTR6 P50406 1/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4913576 0.90 CXCR4 (0.69) CXCR4NR1H2ALDH1A1POLBLMNA
SCHEMBL4923600 0.89 CXCR4 (0.62) CXCR4MAOAMAOBCASP3NR1H2
SCHEMBL4748942 0.83 ALDH1A1 (0.61) CXCR4MCHR1ALDH1A1POLBGRM2
SCHEMBL4924436 0.78 CXCR4 (0.79) CXCR4NR1H2ALDH1A1LMNAKMT2A
SCHEMBL17468364 0.72 CXCR4 (0.55) CXCR4ALDH1A1POLBLMNASMN1; SMN2
SCHEMBL25205014 0.72 HSD17B10 (0.53) ALDH1A1POLBSMN1; SMN2KMT2A
SCHEMBL4923100 0.71 CXCR4 (1.00) CXCR4ALDH1A1LMNAKMT2A
SCHEMBL14470114 0.71 KMT2A (0.70) CXCR4MAOAMAOBCASP3ALDH1A1
SCHEMBL4751222 0.71 SMN1; SMN2 (0.58) CXCR4ALDH1A1POLBLMNASMN1; SMN2
SCHEMBL4923111 0.70 CXCR4 (1.00) CXCR4ALDH1A1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea METASTATIX, INC. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea MKI67, CCNI, CDKN1A CXCR4 242/4885MAOA 2611/4885MAOB 2303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.